Protein / target
Mu-type opioid receptor
Protein at a glance
Biological role
Voltage-gated calcium channel activity
Primary system
Nervous system
Strongest disease association
opioid use disorder
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
72 approved · 16 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G protein complex and subsequent exchange of GDP for GTP in the G protein alpha subunit leading to dissociation of the G protein complex with the free GTP-bound G protein alpha and the G protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G protein-coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)
Subcellular location
Domains and Gene Ontology detail (34)Hide
Gene Ontology
- Caxon
- Cdendrite
- Cendoplasmic reticulum
- Cendosome
- CGolgi apparatus
- Cneuron projection
- Cperikaryon
- Cplasma membrane
- Csynapse
- Fbeta-endorphin receptor activity
- FG protein-coupled receptor activity
- FG-protein alpha-subunit binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
G protein-coupled signalling
- ·Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478,…
- ·G protein-coupled receptor activity
- ·adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway
- ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
Synaptic signalling
- ·synapse
Kinase signalling
- ·Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478,…
Immune signalling
- ·Interleukin-4 and Interleukin-13 signaling
View underlying pathways (6)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Mu opioid receptor agonist
Appears in clinical studies involving Chronic pain, Pain, cancer, pain agnosia
Mu opioid receptor agonist
Appears in clinical studies involving drug dependence, opiate dependence, overdose, Chronic pain
Mu opioid receptor agonist
Appears in clinical studies involving Pain, Chronic pain, drug dependence, Back pain
Mu opioid receptor agonist
Opioid receptors; mu/kappa/delta antagonist
Appears in clinical studies involving alcohol dependence, Overweight, Obesity, Borderline personality disorder
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 751 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 88 total
Pain · drug dependence
Pain · Cough · Chronic pain
opiate dependence
Constipation · Pain · gastroparesis
constipation disorder · Pain · Constipation
Constipation · Constipation · acute pancreatitis
diabetic neuropathy · cancer pain · Pain
Chronic pain · Pain · cancer
Pain · postpartum depression · acute graft versus host disease
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 4 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: BUPRENORPHINE (ANDA204937)
- Label change
Label change: BUPRENORPHINE (ANDA204937)
- Label change
Label change: BUPRENORPHINE (ANDA204937)
- Industry developmentMany U.S. teens underestimate fentanyl’s deadly risk
- Supplemental approval
Supplemental approval: BUPRENORPHINE (ANDA207490)
- Supplemental approval
Supplemental approval: FENTANYL (ANDA202097)
- Supplemental approval
Supplemental approval: OXYCODONE AND ACETAMINOPHEN (ANDA210644)
- Supplemental approval
Supplemental approval: BUPRENORPHINE (ANDA210272)
- Supplemental approval
Supplemental approval: BUPRENORPHINE (ANDA211586)
- Supplemental approval
Supplemental approval: BUPRENORPHINE (ANDA204937)
- Supplemental approval
Supplemental approval: BUPRENORPHINE (ANDA210162)
- Supplemental approval
Supplemental approval: OXYCODONE (NDA208090)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.